Ethambutol
Myambutol — ethambutol hydrochloride
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Pulmonary tuberculosis (drug-susceptible) | Adults; children ≥13 years (FDA PI); guidelines support younger children | Combination therapy (4th drug in intensive phase) | FDA Approved |
| Re-treatment of TB after prior treatment failure | Adults | Combination therapy | FDA Approved |
Ethambutol is a bacteriostatic agent that serves as the fourth drug in the standard TB intensive-phase regimen (alongside isoniazid, rifampin, and pyrazinamide). Its primary role is to prevent the emergence of resistance to the other agents, particularly when isoniazid susceptibility is unknown or resistance is suspected. Ethambutol is discontinued once isoniazid susceptibility is confirmed, typically within the first 2 months. It also has activity against several non-tuberculous mycobacteria.
Mycobacterium avium complex (MAC) infection: Component of multi-drug regimens for pulmonary and disseminated MAC disease, typically 15–25 mg/kg daily with a macrolide and rifamycin. Evidence quality: High (ATS/IDSA guidelines).
Mycobacterium kansasii infection: Part of combination therapy with isoniazid and rifampin. Evidence quality: High (ATS/IDSA guidelines).
TB meningitis: Used in the intensive phase, though CSF penetration is limited without meningeal inflammation. Evidence quality: Moderate (guideline-supported).
Dosing
Adult Weight-Based Dosing (ATS/CDC/IDSA)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active TB intensive phase — daily (40–55 kg) | 800 mg once daily | 800 mg once daily | 1600 mg/day | Part of 4-drug regimen; discontinue once INH susceptibility confirmed Dose based on lean body weight |
| Active TB intensive phase — daily (56–75 kg) | 1200 mg once daily | 1200 mg once daily | 1600 mg/day | Most common weight band |
| Active TB intensive phase — daily (76–90 kg) | 1600 mg once daily | 1600 mg once daily | 1600 mg/day | Maximum daily dose per ATS/CDC/IDSA |
| Active TB — twice-weekly DOT (40–55 kg) | 2000 mg twice weekly | 2000 mg twice weekly | 4000 mg/dose | Only under DOT |
| Active TB — twice-weekly DOT (56–75 kg) | 2800 mg twice weekly | 2800 mg twice weekly | 4000 mg/dose | Higher individual doses for intermittent schedule |
| Active TB — twice-weekly DOT (76–90 kg) | 4000 mg twice weekly | 4000 mg twice weekly | 4000 mg/dose | Max twice-weekly dose |
| Re-treatment TB (prior treatment failure) | 25 mg/kg once daily | 15 mg/kg once daily (after 60 days) | 2500 mg/day | Reduce to 15 mg/kg after initial 60 days at 25 mg/kg FDA PI recommendation for re-treatment |
| MAC pulmonary disease — daily | 15 mg/kg once daily | 15 mg/kg once daily | 1600 mg/day | Combined with macrolide + rifamycin ATS/IDSA MAC guidelines; duration until culture negative ≥1 year |
Pediatric Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Active TB intensive phase — daily (<40 kg) | 15–25 mg/kg once daily | 15–25 mg/kg once daily | 2500 mg/day (AAP) | ATS/CDC/IDSA and AAP guidelines; WHO recommends 20 mg/kg FDA PI: not recommended <13 years; guidelines support use in younger children |
| Active TB — twice-weekly DOT | 50 mg/kg twice weekly | 50 mg/kg twice weekly | 2500 mg/dose | Only under DOT |
In drug-susceptible TB, ethambutol is included empirically as the 4th drug during the intensive phase to guard against unrecognised isoniazid resistance. Once susceptibility testing confirms the isolate is sensitive to both isoniazid and rifampin, ethambutol can be safely discontinued — typically within the first 2 months. If INH resistance is found, ethambutol is continued throughout therapy. In MAC infections, ethambutol is a core component maintained for the full treatment duration.
Pharmacology
Mechanism of Action
Ethambutol exerts its bacteriostatic effect by inhibiting the enzyme arabinosyl transferase (encoded by the embB gene), which is involved in the polymerisation of arabinogalactan, a key structural component of the mycobacterial cell wall. By disrupting arabinogalactan synthesis, ethambutol impairs cell wall integrity and increases permeability, enhancing the efficacy of companion drugs. Ethambutol is active only against actively growing organisms and has no activity against dormant bacilli. Resistance arises through mutations in the embB gene, with no cross-resistance to other first-line TB drugs.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | 75–80% absorbed from GI tract; Tmax 2–4 h; Cmax 2–5 mcg/mL at 25 mg/kg | Food does not significantly affect absorption. Can be taken with or without food. Aluminum-containing antacids reduce absorption by ~20%. |
| Distribution | Widely distributed to lungs, kidneys, saliva; limited CSF penetration (10–50% of plasma); 20–30% protein bound | CSF penetration improves with meningeal inflammation but remains lower than isoniazid or pyrazinamide. Concentrates in erythrocytes (RBC levels 2× plasma). |
| Metabolism | Hepatic oxidation to inactive aldehyde and dicarboxylic acid metabolites (~15% of dose) | Hepatic impairment does not significantly alter pharmacokinetics. Ethambutol can be used safely in liver disease. |
| Elimination | ~50% excreted unchanged in urine; ~15% as metabolites; ~20% in feces; t½ ~3–4 h | Primarily renally excreted — dose reduction required in renal impairment. Serum levels undetectable by 24 h in normal renal function. Accumulation risk in CKD increases optic toxicity risk. |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Optic neuropathy (at 15 mg/kg/day) | <1–2.5% | Dose-dependent: <1% at ≤15 mg/kg; 5–6% at 25 mg/kg; 18–33% at >35 mg/kg. Presents as decreased visual acuity, red-green colour blindness, central scotomas. Onset typically 2–12 months. |
| Nausea / vomiting / anorexia / abdominal pain | 1–5% | GI effects are generally mild; taking with food may help |
| Arthralgia / joint pain | 1–5% | May be related to hyperuricemia (less common than with pyrazinamide) |
| Hyperuricemia | 1–5% | Due to decreased renal uric acid clearance; less pronounced than pyrazinamide. Acute gout can be precipitated. |
| Headache / dizziness / malaise | 1–3% | Usually mild and self-limiting |
| Rash / pruritus / dermatitis | 1–3% | Discontinue if severe or exfoliative |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Optic neuropathy (irreversible vision loss) | 1–2% overall; dose-dependent | Typically 2–4 months; range 1–12 months | Immediate discontinuation. Ophthalmology referral. Vision usually recovers over weeks to months, but irreversible blindness has been reported even with prompt cessation. |
| Hepatotoxicity (including fatalities) | Uncommon; difficult to attribute in multi-drug regimens | Variable | Monitor LFTs; discontinue if significant elevation. May be related to concurrent INH/RIF/PZA. |
| Hypersensitivity syndrome (rash + eosinophilia + organ inflammation) | Rare | Weeks to months | Discontinue ethambutol; organ-specific treatment as needed. Syndrome may include hepatitis, pneumonitis, nephritis, myocarditis, pericarditis. |
| Thrombocytopenia / leukopenia / neutropenia | Rare | Variable | Check CBC; discontinue if significant cytopenias confirmed |
| Anaphylaxis / anaphylactoid reaction | Very rare | Minutes to hours | Emergency treatment with epinephrine; permanent discontinuation |
| Peripheral neuritis (numbness/tingling of extremities) | Rare | Weeks to months | Assess for concurrent neurotoxic agents (INH); consider discontinuation if symptoms progress |
Ethambutol optic neuropathy (EON) is the most clinically significant adverse effect. Risk is strongly dose-dependent: <1% at ≤15 mg/kg/day, 5–6% at 25 mg/kg/day, and 18–33% at >35 mg/kg/day. Additional risk factors include renal impairment (delayed excretion), age >65, hypertension, and prolonged treatment duration. Symptoms include decreased visual acuity, loss of red-green colour discrimination, central or cecocentral scotomas, and visual field constriction. Onset is typically between 2 and 4 months but can occur at any time. Vision usually recovers over weeks to months after discontinuation, but irreversible blindness has been reported even with prompt cessation. All patients require baseline and monthly ophthalmologic assessment while on ethambutol.
Drug Interactions
Ethambutol has a limited drug interaction profile. It is not a significant CYP450 inducer or inhibitor. The main clinically relevant interactions involve absorption and additive toxicity concerns.
Monitoring
- Visual Acuity & Colour VisionBaseline; monthly during therapy
RoutineThe single most important monitoring parameter. Perform Snellen visual acuity (each eye separately), Ishihara or Hardy-Rand-Rittler colour plates, and Amsler grid at baseline. Repeat monthly while on ethambutol, especially at doses ≥15 mg/kg. Discontinue immediately if any deterioration is detected. Consider formal Humphrey visual field testing if available. - Renal Function (Creatinine, CrCl)Baseline; periodically
RoutineEthambutol is primarily renally excreted. Dose adjustment is required in renal impairment. Declining renal function during therapy increases the risk of drug accumulation and optic toxicity. - Hepatic Enzymes (ALT, AST)Baseline; periodically
RoutineHepatotoxicity, including fatalities, has been reported (often in multi-drug regimens). Baseline and periodic LFTs are recommended per the FDA PI. - Serum Uric AcidBaseline; as clinically indicated
Trigger-basedMonitor in patients with history of gout or concurrent pyrazinamide use. Ethambutol can elevate uric acid and precipitate acute gout. - CBCBaseline; as clinically indicated
Trigger-basedThrombocytopenia, leukopenia, and neutropenia have been reported. Check if bruising, bleeding, or signs of infection develop.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to ethambutol or any component
- Pre-existing optic neuritis (unless clinical judgement deems benefit outweighs risk)
- Patients unable to report visual changes — young children (FDA PI: <13 years, though guidelines support use with monitoring), unconscious patients, or those with cognitive impairment
Relative Contraindications (Specialist Input Recommended)
- Renal impairment: Primary excretion route; dose reduction and serum level monitoring required. Increased risk of optic neuropathy from drug accumulation.
- Pre-existing visual defects (cataracts, diabetic retinopathy, recurrent ocular inflammation): Makes visual monitoring more difficult; heightened caution needed.
- History of gout: Ethambutol can elevate uric acid and precipitate attacks.
Use with Caution
- Elderly (>65 years): Higher risk of optic neuropathy; age-related renal decline may cause accumulation
- Pregnancy: Category C; ophthalmic abnormalities reported in infants exposed in utero. Use only if benefit outweighs risk.
- Concurrent pyrazinamide: Additive hyperuricemia potential
Ethambutol may produce decreases in visual acuity due to optic neuritis. This effect is dose- and duration-related and is generally reversible when the drug is discontinued promptly. However, irreversible blindness has been reported. Baseline and periodic ophthalmologic evaluation (including visual acuity, colour discrimination, and visual fields) is mandatory. Patients who cannot appreciate or report visual changes should not receive ethambutol.
Liver toxicities including fatalities have been reported with ethambutol therapy. Baseline and periodic assessment of hepatic function should be performed.
Patient Counselling
Purpose of Therapy
Ethambutol is one of four antibiotics used together to treat tuberculosis. It helps prevent the TB bacteria from becoming resistant to the other medicines. You will usually take ethambutol for the first 2 months of treatment, unless your doctor tells you otherwise.
How to Take
Take ethambutol once daily as a single dose. It can be taken with or without food. Do not take aluminum-containing antacids within 4 hours of your ethambutol dose. Complete the full course as prescribed.
Sources
- Myambutol (ethambutol hydrochloride) prescribing information. FDA label, revised 2013. FDA LabelPrimary regulatory source for approved indications, dosing, contraindications, optic neuropathy warnings, and PK data.
- Ethambutol Tablets prescribing information. Various manufacturers. Drugs.com PISupplementary PI source for generic ethambutol formulations, confirming dosing and adverse reaction data.
- Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy. Curr Opin Ophthalmol. 2017;28(6):545–551. DOIComprehensive review of EON prevalence, dose-response data, risk factors, and monitoring protocols informing the side effects and monitoring sections.
- Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol. 2008;28(4):265–268. DOILandmark perspective on the global burden of EON and the imperative for systematic visual monitoring.
- Nahid P, Dorman SE, Alipanah N, et al. Official ATS/CDC/IDSA clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. DOIComprehensive active TB guidelines providing weight-band dosing tables for ethambutol in all regimen schedules.
- Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. DOIATS/IDSA NTM guidelines providing ethambutol dosing for MAC and M. kansasii infections.
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952. DOIATS consensus on hepatotoxicity monitoring during multi-drug TB therapy.
- Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med. 1997;3(5):567–570. DOIFoundational study identifying the embB gene target and resistance mechanisms for ethambutol.
- Sudhakar P, Acharya K, Kini TA. Ethambutol optic neuropathy. Front Neurol. 2025;16:1626909. Full textRecent comprehensive review of EON pathophysiology, dose-dependent incidence data, and screening modalities.
- StatPearls. Ethambutol. National Library of Medicine, 2024. NCBIComprehensive pharmacology review covering PK, dosing, pediatric considerations, and adverse effects.
- Drugs.com. Ethambutol monograph for professionals. Drugs.comClinical reference confirming weight-band dosing, renal adjustment guidance, and MAC dosing recommendations.